Anti-thymocyte globulin with CsA and MMF as GVHD prophylaxis in nonmyeloablative HLA-mismatched allogeneic HCT.

Bone Marrow Transplant · 2021 · PMC8214052 · PMID 34148060

Europe PMC DOI

hedged sentence

0.0700

closest p · 1.4× alpha

0.0700

boldest claim

The sentences

showed a trendP = 0.07so close (0.05 < p ≤ 0.1)

Class I mismatch was also significantly related to OS ( P = 0.01) and DRI showed a trend for OS ( P = 0.07), Supplementary Table .

also in 53,322 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.